Case Study: Top 30 Global Pharma Company achieves rapid, actionable site feedback to guide COVID-19 trial decisions with Teckro

Real-Time Site Feedback Guides Sponsor Decisions Could Telemedicine Help Sites Resume Trials Disrupted by COVID-19

Top 30 Global Pharma Company faced halted enrollment on a Phase III cardiovascular study (1,134 sites across 40 countries, 17,400 participants) when COVID-19 disrupted site operations. To quickly validate whether telemedicine could help resume the trial, the sponsor used Teckro’s survey capability on the Teckro platform (Teckro Survey) to gather real-time site feedback.

Teckro deployed a 10-question survey via Teckro alerts and dashboard, targeting active site staff; the one-week campaign achieved an average 18% response rate across 15 countries and 31% among the top 50 US enrolling sites. Results showed more than half of sites had reopened enrollment, over 60% had taken alternative follow-up actions, 69% reported their institution offered telemedicine but only 43% would use a sponsor-provided system, and 79% said home-visit approvals would take more than four weeks—leading the sponsor to conclude telemedicine wouldn’t meaningfully restart the study. Teckro’s quick, targeted survey and dashboard export enabled the sponsor to make an informed, measurable operational decision in one week.